Introduction
Vascular alterations are a common feature in patients with diabetes mellitus and consist of abnormal growth, proliferation and migration of cells. In previous studies, we demonstrated that, in early diabetes, transforming growth factor-␤ 1 (TGF-␤ 1) plays an important role in mediating vascular dysfunction in both renal microvascular smooth muscle cells and in aortic smooth muscle cells [1] .
One of the prominent vascular changes induced by diabetes and mediated by TGF-␤ is decreased sensitivity of vascular smooth muscle cells (VSMC) to angiotensin II (Ang II). We previously demonstrated that aortic ring contraction in response to Ang II was impaired in diabetic rats, but completely restored to normal in diabetic rats treated with anti-TGF-␤ 1 antibodies [1] . Further, VSMC isolated from diabetic rat aorta exhibited impaired Ang II-induced cytosolic calcium signaling, but calcium signaling was normal in VSMC from diabetic rats treated with anti-TGF-␤ 1 antibodies in vivo. Further, the effect of diabetes on Ang II-induced calcium signaling was replicated in vitro by administration of TGF-␤ 1 and TGF-␤ 2 to aortic VSMC in culture. As a possible mechanism, a downregulation of inositol 1,4,5-trisphosphate receptors may be involved in TGF-␤ -mediated impairment of Ang II-induced calcium signaling in VSMC [1] .
Ang II signaling is mediated through 2 types of receptors, the Ang II type 1 (AT 1 ) and the Ang II type 2 (AT 2 ) receptor. In rodents, 2 distinct isoforms or subtypes of AT 1 exist, AT 1a and AT 1b , with the AT 1a being the predominant isoform in VSMC. Ang II-mediated vascular contraction and vascular hypertrophy are mediated mainly through AT 1 [2] . AT 1 is a G protein-coupled 7-transmembrane receptor that signals through several signaling pathways. Ang II-induced vascular contraction is mediated mainly through the PLC/IP 3 /calcium route, while Ang II-induced vascular remodeling in diabetes is mediated mainly through the MAPK p44/42 kinase signaling pathway [2] . The involvement of the MAPK p44/42 pathway in vascular remodeling has been demonstrated in several in vitro experiments. Inhibition of the MAPK p44/42 pathway with the MAP kinase (MEK) inhibitor PD98059 completely blocked the growth stimulatory effects of Ang II on VSMC [2] . In addition, the migration of VSMC by Ang II is mediated by the MAPK p44/42 pathway, although the signaling through MAPK p38 appears to be predominant [3] .
Besides these effects on proliferation and migration, Ang II-mediated activation of the MAPK p44/42 pathway is involved in the accumulation of extracellular matrix in VSMC. A key mediator in this process is plasminogen activator inhibitor-1 (PAI-1), an inhibitor of the conversion of inactive plasminogen to active plasmin. Plasmin is able to degrade fibrin and extracellular matrix components and therefore PAI-1 contributes to an increased risk of thrombosis and atherosclerotic plaque formation [4] [5] [6] [7] . The expression of PAI-1 can be induced by both Ang II and TGF-␤ 1, a process that can be inhibited by the MEK/MAPK p44/42 inhibitor PD98059 [8] , although other members of the MAPK signaling may be involved [9, 10] .
Although we have reported an inhibitory effect of TGF-␤ 1 on the Ang II-induced activation of the PLC/IP 3 / calcium route, the effect of TGF-␤ 1 on Ang II-induced activation of the MAPK p44/42 signaling pathway in VSMC is still unclear. Therefore, the aim of this study is to investigate the effect of TGF-␤ 1 on Ang II-induced activation of the MAPK p44/42 pathway in cultured rat aortic smooth muscle cells (RASMC).
Methods

Cell Culture
Primary RASMC were isolated from rat aorta as described earlier [1] . Cells were cultured in DMEM supplemented with 1,000 mg/l glucose, L -glutamine, 25 m M HEPES, pyruvate (Gibco BRL), 10% of bovine calf serum (PAA Laboratories), 100 U/ml of penicillin and 100 g/ml streptomycin (Gibco BRL) in a humidified incubator at 37 ° C and 5% CO 2 . When cells reached confluence, they were passaged in a 1: 3 ratio with trypsin EDTA (Gibco BRL). For all experiments, cells were used between passage 3 and 12.
Western Blotting Cells were washed 3 times using ice-cold phosphate-buffered saline (PBS) and subsequently lysed in 300 l of ice-cold RIPA buffer (1% Igepal ca-630, 1% SDS, 5 mg/ml sodium deoxycholate, 1 m M sodium orthovanadate, 10 m M ␤ -mercapto-ethanol, 40 g/ ml PMSF, 100 g/ml benzamidine, 500 ng/ml pepstatin A, 500 ng/ml leupeptine and 500 ng/ml aprotinin in PBS). Protein concentrations were determined using Bio-Rad protein assay. On a 7.5% SDS-PAGE gel, 10 g of total protein was run, transferred to nitrocellulose and immunoblotted with the MAPK p44/42 (1: 1,000 dilution) antibody (sc-7383; Santa-Cruz).
Saturation Binding Assay RASMC cells were cultured on 24-well cell culture plates. Twenty-four hours before the start of the binding assay, the medium was replaced with fresh medium or fresh medium supplemented with 10 ng/ml TGF-␤ 1. After 24 h of incubation, cells were washed 3 times with HBSS at 37 ° C. Tritium-labeled candesartan ([ 3 H]candesartan; 629 Bq/mmol) was added in a concentration series of 0-10 n M in a volume of 0.5 ml HBSS. Nonspecific binding was determined by adding 1 M cold candesartan. After 1 h of incubation at 37 ° C, plates were placed on ice and the cells were washed 3 times with ice-cold PBS. Cells were subsequently lysed with 500 l of 1 N NaOH and total protein content of the lysate was determined using a DC protein assay (Bio-Rad). Total protein content did not differ between groups and the remaining lysate (490 l) was transferred to a scintillation vial containing 3 ml of scintillation fluid. Vials were counted for 3 min in a scintillation counter. Analysis of the binding data was performed according to the method of Scatchard.
Real-Time PCR
The expression of AT 1 (rat vascular AT 1a ), PAI-1, fibronectin, collagen I and III mRNA in rat aortic smooth cells was analyzed using real-time 2-step quantitative RT-PCR. Quantification was performed with SYBR Green PCR reagents (Molecular Probes Europe) and an ABI PRISM 5700 sequence detection system (Applied Biosystems). A 50-l PCR mixture contained 0. 
AT 1 Promoter Assay
An 854-bp genomic DNA fragment corresponding to position -828 to +25 of the transcription initiation site of the rat AT 1a receptor was cloned in pGL3 basic reporter vector (Promega). RASMC cells were cultured in a 24-well plate and infected with 2 g of AT 1 reporter vector per well. Forty-eight hours after infection, cells were treated with TGF-␤ 1 (10 ng/ml). Luciferase activity was determined using the Luciferase Assay System (Promega).
Real-Time PCR-Based Nuclear Runoff Assay
RASMCs were cultured on 21.5-cm 2 Nunclon Delta dishes (Nunc). When cells reached confluence, TGF-␤ 1 was supplemented to the medium with an end concentration of 10 ng/ml. After 4 h, nuclei were isolated with the nuclei EZ prep isolation kit (Sigma) according to the manufacturer's protocol. Nuclei were dissolved in 250 l of Nuclei EZ storage buffer. Directly after nuclei isolation, 200 l of nuclei suspension were split into 2 aliquots. One hundred microliters of 20% glycerol, 30 m M Tris-HCl, pH 8.0, 2.5 m M MgCl2, 150 m M KCl, 1 m M DTT and 40 U of RNasin (Promega) were added to each aliquot; 0.5 m M ribonucleotide mix (rNTPs; New England Biolabs) were added to one aliquot, while no rNTPs were added to the second aliquot. After 30 min at 30 ° C, nuclei were centrifuged at 500 g for 5 min at 4 ° C and the pellet was resuspended in 350 l RA1 lysis buffer (Macherey Nachel) with 3.5 l of ␤ -mercapto-ethanol. RNA was subsequently isolated with the nucleospin RNA II kit (Machery Nachel) according to the manufacturer's protocol. AT 1 mRNA levels were analyzed by real-time PCR.
Proliferation Assay
Cells were seeded in 96-well plates (Nunc) at 33% confluence. The next day, cells were silenced through replacement of the cul- 
Statistical Analyses
Results are presented as means 8 SEM, unless indicated otherwise. Differences between concentration-response curves were analyzed using repetitive-measurement ANOVA (SigmaStat 1.01; Jandel Scientific) and differences between other variables were tested using Student's t test. Differences were considered significant at p ! 0.05.
Results
Stimulation of RASMC with Ang II resulted in a dosedependent increase in phosphorylated MAPK p44 and p42 ( fig. 1 a) . In control cells, maximal levels of phosphorylated p44/42 were observed at 3 n M Ang II. Preincubation of the cells for 24 h with TGF-␤ 1 (10 ng/ml) resulted in a right shift of the dose-response curve to Ang II ( fig. 1 a) , showing a 50-fold increase in EC 50 . Preincubation for 24 h with TGF-␤ 1 (10 ng/ml) did not affect basal phosphorylated MAPK p44/42 levels ( fig. 1 a; 0 M Ang II).
We next examined the dose dependency of this Ang II-inhibiting effect of TGF-␤ 1 on phosphorylation of p42/p44 ( fig. 1 b) . TGF-␤ 1 impaired Ang II-induced MAPK p44/42 signaling in a dose-dependent manner with an apparent maximal effect at 10 ng/ml, although higher concentrations were not investigated.
To establish the mechanism of TGF-␤ 1-impaired Ang II-induced MAPK p44/42 signaling, we first examined regulation of AT 1 fig. 2 ) . Incubation of cells with TGF-␤ 1 significantly decreased B max to 680 8 18 dpm, without an effect on K d (0.07 8 0.01 n M ). These data demonstrate pretreatment with TGF-␤ 1 to result in a downregulation of AT 1 , without changes in receptor affinity for candesartan.
We next investigated whether the timing of AT 1 downregulation matched the timing of the inhibition of Ang II-mediated MAPK p44/42 signaling. RASMC cells were incubated with TGF-␤ 1 (10 ng/ml) at different incubation times and both the levels of specific candesartan binding and phosphorylated p44/p42 were determined ( fig. 3 ). These results demonstrate that the timing of the inhibition of Ang II-mediated MAPK p44/42 signaling parallels the downregulation of AT 1 .
To establish the mechanism of AT 1 downregulation by TGF-␤ 1, we determined AT 1 mRNA levels in RASMC after incubation with TGF-␤ 1 (10 ng/ml) with different incubations times ( fig. 4 a) . Incubation with TGF-␤ 1 for 4 h and longer resulted in decreased AT 1 mRNA levels. Next, we investigated whether decreased AT 1 mRNA levels by TGF-␤ 1 were the result of decreased transcriptional activity of the AT 1 gene. Incubation of RASMC with TGF-␤ 1 (10 ng/ml) resulted in decreased AT 1 promoter activity after 12 h of incubation ( fig. 4 b) . These data were further supported by the real-time PCR-based nuclear runoff assay. Thirty minutes of in vitro transcription resulted in a 1.3-fold increase in AT 1 mRNA in control cells, whereas 4-hour treatment of TGF-␤ 1 totally blocked transcription of AT 1 mRNA ( fig. 5 a) .
Further, we investigated whether the decrease in AT 1 mRNA levels by TGF-␤ 1 results from changes in AT 1 mRNA stability. To this end, all transcription of mRNA was blocked by incubating the cells with actinomycin D prior to administration of TGF-␤ 1. In control cells, the half-life of AT 1 mRNA levels was approximately 6 h. Incubation with TGF-␤ 1 did not affect the half-life of AT 1 mRNA levels ( fig. 5 b) , resulting in identical rates of AT 1 mRNA decay for both TGF-␤ 1-treated and control cells. Also, identical AT 1 mRNA decay rates were observed in untreated and treated cells when TGF-␤ 1 was added to the cells 1 h before the addition of actinomycin D (data not shown). Therefore, incubation with TGF-␤ 1 does not affect the stability of the AT 1 mRNA.
To assess the functional implications of the interaction of TGF-␤ and Ang II signaling, the proliferation and expression of profibrotic genes was assessed. Stimulation of RASMC with Ang II resulted in a dose-dependent increase in proliferation in control cells. TGF-␤ 1 (10 ng/ml) itself increased proliferation slightly, however, 4 h of preincubation of the cells with TGF-␤ 1 (10 ng/ml) completely blocked Ang II-induced proliferation ( fig. 6 ).
Finally, we examined the expression of the fibrotic markers PAI-1, fibronectin, collagen I and collagen III ( fig. 7 ) . Stimulation of RASMC with Ang II resulted in increased mRNA levels of PAI-1 and fibronectin. TGF-␤ 1 (10 ng/ml) itself increased PAI-1 expression. Preincubation with TGF-␤ 1 (10 ng/ml) strongly augmented Ang II-induced PAI-1 expression, indicating a synergistic effect of TGF-␤ 1 and Ang II on PAI-1 expression. The expression of collagen I was decreased after exposure to 3 n M Ang II. The expression of collagen III was not affected by Ang II or TGF-␤ 1.
Discussion
The present study demonstrates that TGF-␤ 1 inhibits the Ang II-induced MAPK p44/42 signaling pathway in cultured RASMC. In TGF-␤ 1-pretreated cells, we observed an inhibition of Ang II-induced phosphorylation of MAPK p44/42 and a reduction in AT 1 density, without an effect on receptor affinity for candesartan. In addition, AT 1 mRNA levels were downregulated and accompanied by a decrease in transcriptional activity of the AT 1 gene, without a reduction in AT 1 mRNA stability.
The kinetics of the inhibition of Ang II-mediated MAPK p44/42 signaling by TGF-␤ 1 closely followed the kinetics of AT 1 mRNA downregulation. In addition, the downregulation of AT 1 mRNA levels was accompanied by a reduction in AT 1 promoter activity, although the reduction in AT 1 promoter activity lagged behind the downregulation of AT 1 mRNA levels, probably due to the stability of the luciferase reporter protein. Furthermore, the nuclear runoff assay demonstrated that pretreatment with TGF-␤ 1 for 4 h resulted in decreased AT 1 mRNA levels and that AT 1 gene transcription had halted. As the downregulation of AT 1 mRNA levels by TGF-␤ 1 did not involve changes in the stability of AT 1 mRNA, we conclude that the downregulation of AT 1 mRNA by TGF-␤ 1 is the result of decreased transcription of the AT 1 gene. Downregulation of AT 1 levels has been described previously in TGF-␤ 1-treated primary renal proximal tubule cells [11] . Moreover, decreased transcriptional activity of the AT 1 promoter by TGF-␤ appears to be a general mechanism for downregulation of AT 1 levels in multiple tissues in experimental diabetes [11, 12] . Indeed, decreased levels of AT 1 in VSMC exposed to high glucose was already reported in 1992 [12] , although the involvement of TGF-␤ 1 and its effects on MAPK p44/42 signaling has not been demonstrated before. In contrast to our findings, transcriptional upregulation of human AT 1 by TGF-␤ 1 has recently been reported in human lung fibroblasts [13] . However, VSMC contain a specific set of transcription factors [14] and therefore the difference in AT 1 regulation may arise from cell type-specific gene regulation. Furthermore, in rodents, 2 subtypes of the AT 1 receptor exist, while in humans only a single AT 1 subtype is present. The promoters of the human AT 1 and rat vascular AT 1a genes differ considerably and may explain the difference in TGF-␤ 1-mediated AT 1 regulation in human fibroblasts and rat VSMC. The decreased transcription of the AT 1 gene resulted in a reduction in the number of binding sites for the specific AT 1 blocker candesartan, indicating a reduction in the number of AT 1 receptors on the plasma membrane of RASMC pretreated with TGF-␤ 1. Previously, it has been demonstrated that the specific downregulation of AT 1 mRNA levels using siRNA against AT 1 results in decreased AT 1 receptor levels and inhibition of MAPK p44/42 signaling [15] . We therefore conclude that the inhibition of Ang II-induced MAPK p44/42 signaling in TGF-␤ 1-pretreated RASMC is most likely caused by decreased gene transcription of the AT 1 gene and decreased AT 1 receptor levels. It is, however, unclear how the observed moderate decrease in AT 1 receptor levels could result in an increase in the EC 50 of Ang II by a factor of 50. Possibly, posttranslational modifications to the AT 1 could alter the affinity of the AT 1 for Ang II, as has been demonstrated previously [16] . However, we did not observe a change in the affinity of the AT 1 for the competitive antagonist candesartan after TGF-␤ 1 pretreatment. It is therefore unlikely that pretreatment with TGF-␤ 1 results in conformational changes to the Ang II-binding site of the AT 1 . Alternatively, inhibition of downstream coupling of the AT 1 to G proteins and second-messenger systems may be additional mechanisms for inhibiting Ang II-induced MAPK p44/42 signaling in TGF-␤ 1-pretreated RASMC. Previously, it has been demonstrated that TGF-␤ 1 could inhibit the epidermal growth factor (EGF) and ␣ 1B-adrenergic receptors by modifying their phosphorylation status [17, 18] . It is, however, unclear whether TGF-␤ 1 could have similar effects on AT 1 receptors.
Several studies have demonstrated that the hypertrophic effects of Ang II on VSMC in experimental models of diabetes are mediated through the MAPK p44/42 signaling pathway [2, 19] . In a recent paper by Wang et al. [20] , it has been demonstrated that activation of AT 1 by Ang II in VSMC results in the activation of the Smad2/3 signaling pathway, a profibrotic pathway that is also activated by TGF-␤ . Our study demonstrates for the first time that TGF-␤ 1 inhibits the Ang II-mediated MAPK p44/42 signaling pathway. Therefore, the cross-talk between the Ang II and TGF-␤ 1 signaling pathways appears to be bidirectional.
We demonstrated that Ang II-mediated proliferation of RASMC could be completely inhibited by pretreatment with TGF-␤ 1. This is in line with a previous study demonstrating that Ang II-induced proliferation of human VSMC was mediated through AT 1 and MEK [2] . Therefore, the inhibition of Ang II-mediated proliferation of TGF-␤ 1-pretreated RASMC is most likely caused by the impaired MAPK p44/42 signaling. Furthermore, it has been demonstrated that TGF-␤ 1 could also inhibit EGF-mediated MAPK p44/42 signaling and proliferation of human epithelial cells through inhibition of the EGF receptor [17] . Thus, TGF-␤ 1-mediated inhibition of MAPK p44/42 signaling and proliferation appears to apply to multiple receptor systems and cell types.
In contrast to the effect of TGF-␤ 1 pretreatment on proliferation, inhibition of MAPK p44/42 signaling by pretreatment with TGF-␤ 1 augmented Ang II-induced PAI-1 expression in RASMC. This is surprising, as several studies have demonstrated that PAI-1 expression is dependent on MEK [8, [21] [22] [23] [24] . Possibly, PAI-I expression may be induced through other MAPK routes. It has been demonstrated that both TGF-␤ 1 and Ang II can signal through the reactive oxygen species p38MAP/JNK route [25, 26] . Indeed, in fibroblasts, TGF-␤ 1-induced PAI-1 expression is dependent on this pathway [25] . Furthermore, PAI-1 expression may be mediated by HIF-1 ␣ expression through Ang II-mediated stimulation of AT2 receptors [27] . However, the involvement of the p38MAP/ JNK or other pathways in the synergistic upregulation of PAI-1 by TGF-␤ 1 and Ang II in RASMC remains to be established.
The pathophysiological relevance of the inhibitory effect of TGF-␤ 1 on MAPK p44/42 is still unclear. Previous studies have suggested that the balance between vascular fibrosis and vascular proliferation may be controlled by the relative levels of Ang II and TGF-␤ [20, 28] . Indeed, in our study, pretreatment with TGF-␤ 1 completely inhibited Ang II-induced proliferation of RASMC, while Ang II and TGF-␤ 1 acted synergistically on the increased expression of the early fibrotic marker PAI-1. In recent papers [20, 29, 30 ] , a new model has emerged to describe the interaction between AT 1 and TGF-␤ 1 signaling in vascular remodeling. In these studies, it has been demonstrated that Ang II can directly stimulate the intracellular mediators of TGF-␤ 1 signaling, Smad2 and 3. This activation of Smad2/3 appears to be bimodal in nature. In the initial phase at 15 min, Ang II directly activates Smad2/3 through AT 1 and via MAPK p44/42. In the delayed response to Ang II at 24 h, paracrine production of TGF-␤ 1 maintains Smad3 activation, leading to the activation of profibrotic genes. Our current findings suggest that the inhibition of Ang II-mediated MAPK p44/42 signaling by TGF-␤ 1 may be part of a negative feedback loop that attenuates the direct activation of Smad2/3 by Ang II and inhibits excessive Ang II-mediated smooth muscle cell proliferation.
In conclusion, in this study we provide the pharmacological characteristics of the TGF-␤ 1-induced decrease in Ang II-mediated MAPK signaling in RASMC. We demonstrate that TGF-␤ 1 attenuates Ang II-mediated MAPK p44/42 signaling in RASMC through downregulation of AT 1 levels, which seems mainly dependent on the inhibition of transcriptional activity of the AT 1 gene. Pretreatment with TGF-␤ 1 completely inhibited Ang II-mediated proliferation of RASMC, but synergistically increased Ang II-induced PAI-1 expression.
